This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: Cholesterol

June 2017 Br J Cardiol 2017;24:47-8 doi:http://doi.org/10.5837/bjc.2017.014

A triumph of British cardiovascular medicine: “… and the last can be first…”

Adrian J B Brady

Abstract

The Gospel of Matthew tells us, “…the last can be first…” Nowhere is this truer than the towering UK success of that fundamental cornerstone of cardiovascular prevention, cholesterol-lowering therapy. In 2002, BJC published a paper showing how far the UK lagged behind other countries in Europe when it came to prescribing lipid-lowering drugs.1 At the same time, a number of other very large UK surveys were published.2 All showed that the UK was the sick man of Europe, with limited statin prescribing in the face of a huge burden of cardiovascular disease. Figure 1. Coronary heart disease (CHD) mortality compared to statin sales: Aug

| Full text
Cholesterol: the evolving story – HEART UK 30th annual conference

November 2016 Br J Cardiol 2016;23:136

Cholesterol: the evolving story – HEART UK 30th annual conference

Jaqui Walker

Abstract

The first day of the conference focused on hyperlipidaemia in children. In the opening address Professor Albert Wiegman (University of Amsterdam, The Netherlands) presented compelling data on the importance of screening and identifying children with familial hypercholesterolaemia (FH) so they can be effectively treated and early cardiovascular events prevented. Professor Albert Wiegman (University of Amsterdam, The Netherlands) FH is one of the most common genetic disorders in the world. Both heterozygous, and to a greater extent homozygous FH, can be disabling at a young age and shorten life expectancy. Homozygous familial hypercholesterolae

| Full text
New opportunities for cholesterol lowering: focus on PCSK9 inhibitors

July 2014 Br J Cardiol 2014;21:91–3 doi:10.5837/bjc.2014.021

New opportunities for cholesterol lowering: focus on PCSK9 inhibitors

Peter Sever, Judy Mackay

Abstract

(more…)

| Full text
Hyperlipidaemia and monoclonal antibodies – paying for outcome

July 2014 Br J Cardiol 2014;21:94–5 doi:10.5837/bjc.2014.022

Hyperlipidaemia and monoclonal antibodies – paying for outcome

Gilbert Wagener

Abstract

Dr Gilbert Wagener (Transcrip Partners LLP) Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new target for the treatment of hyperlipidaemia. PCSK9 is apparently complimentary to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibition with statins.6,7 Most advanced in the development path are two monoclonal antibodies (mAbs) against PCSK9, alirocumab (SAR236533) and evolocumab (AMG145), both subcutaneous injectable drugs administered at bi-weekly or four-weekly intervals. Both compounds demonstrated solid reductions in LDL-C, however, dose selection for both focused on the most effective dose and did not consider titration ac

| Full text
In brief

August 2012 Br J Cardiol 2012;19:112–3

In brief

BJCardio Staff

Abstract

EVINCI study completed The prevalence of “significant” coronary artery disease in patients with chest pain symptoms is lower than expected in Europe, according to preliminary findings from the The EValuation of INtegrated Cardiac Imaging (EVINCI) study. Once the final analysis is completed, the EVINCI study is expected to demonstrate that performing adequate non-invasive imaging screening of patients with suspected coronary artery disease could safely avoid invasive procedures in 75 out of 100 patients.  The study will have sufficient power to answer the question of which is the most cost-effective non-invasive imaging strategy for the j

| Full text
In brief

February 2011 Br J Cardiol 2011;18:15-6

In brief

BJ Cardio Staff

Abstract

NHA joins with BHS The Nurses Hypertension Association (NHA) has become part of the British Hypertension Society (BHS) after the BHS decided to invite nurses working in the field of hypertension and cardiovascular disease to be full members of the society. “This acknowledges the shift of care towards specialist nurses, particularly in primary care,” said Naomi Stetson, former head of the NHA. “In the current economic climate, it also made good business sense to have one united organisation.” All members of the NHA are now full BHS members and so the NHA has disbanded. “There is a strong Nurses Working Party within the society, which

| Full text

July 2010 Br J Cardiol 2010;17:163-5

Lp(a) screening recommended by European Atherosclerosis Society 

BJ Cardio Staff

Abstract

A preview of the EAS statement was announced during the EAS 2010 Congress held in June in Hamburg, Germany, by Dr Børge Nordestgaard (University of Copenhagen, Denmark). He said bringing a patient’s Lp(a) level under 50 mg/dL should be a treatment priority, after the management of LDL cholesterol. It is thought that about 20% of people have plasma Lp(a) levels over 50 mg/dL, with no gender differences, but there are some racial differences, with whites and Asians having lower levels while black and Hispanics generally have somewhat higher levels. Since lifestyle appears to have little impact on Lp(a) level, the EAS recommends that 1 to 3 g

| Full text
News from the American Heart Association Scientific Sessions 2009

February 2010 Br J Cardiol 2010;17:13-18

News from the American Heart Association Scientific Sessions 2009

BJCardio editorial staff

Abstract

ARBITER 6: niacin superior to ezetimibe for slowing atherosclerosis Use of extended-release niacin resulted in a significant benefit on atherosclerosis compared with ezetimibe in patients already taking statins in the ARBITER 6-HALTS trial. The trial, presented at the meeting by Dr Allen Taylor (Medstar Research Institute, Washington DC, US), compared two distinct lipid-modifying strategies in patients with known vascular disease already on statins who had LDL-cholesterol levels <100 mg/dL (2.56 mmol/L) and moderately low HDL-cholesterol levels (<50 mg/dL [1.28 mmol/L]). Among the 363 patients enrolled in the study, half were randomised

| Full text

November 2008 Br J Cardiol 2008;15:293

Kellogg’s team up with H·E·A·R·T UK

BJCardio editorial team

Abstract

Kellogg’s Optivita and H·E·A·R·T UK, the cholesterol charity, have teamed up to work together on a programme of joint actions. This will include educational initiatives to support healthcare professionals, particularly practice nurses and dietitians who see people everyday at risk of heart disease due to factors such as high cholesterol, and the provision of practical advice for consumers to help them lower their cholesterol. Optivita has been specifically developed with oat beta-glucan, which has been shown in many studies to help to lower cholesterol.

| Full text

November 2008 Br J Cardiol 2008;15:294–5

Lasker award for the discoverer of statins

BJCardio editorial team

Abstract

Cholesterol and cardiovascular disease Cholesterol has the Jekyll and Hyde characteristics of being both essential to life as a constituent of the body’s cells and of being the prime initiator of atherosclerosis, a process characterised by the formation of cholesterol-rich plaques in arteries. This disorder is the major cause of cardiovascular disease, mainly coronary heart disease and stroke, from which 11 million people die in the world each year. The most common single cause of death in Britain, its eradication is given a high priority by the government. Numerous studies have identified cholesterol, specifically low-density lipoprotein (

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now